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Background: The mechanism of fibrosis during healing after reperfused myocardial infarction (RMI) remains unclear. Secreted-frizzled-related-
protein-2 (sFRP-2) has been suggested to induce protection during acute MI in rats via inhibition of Wnt signaling. Recent evidence in sFRP-2 null 
mice suggests that sFRP-2 can act independently of Wnt, activate Tolloid-like metalloproteinases and enhance collagen deposition and fibrosis 
after MI. Angiotensin II (AngII), acting through AngII type 1 receptors (AT1Rs), has been suggested to regulate post-MI fibrosis and remodeling. AT1R 
antagonists can therefore limit post-MI fibrosis and remodeling. We hypothesized that decreased fibrosis by the AT1R blocker candesartan (CN) 
during healing after RMI might involve decrease in sFRP-2.
Methods: We randomized Sprague-Dawley rats 24 hours after RMI (1 h LAD occlusion; reperfusion) to 3 weeks of oral placebo and CN (30 mg/
kg), and a sham group (no RMI, no drug). We measured left ventricular (LV) remodeling and systolic and diastolic function (echocardiography/
Tissue Doppler), infarct size (planimetry/histopathology), and regional levels of sFRP-2 (Western blot, qRT-PCR), collagens (biochemistry), fibrosis 
(pathology), N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) and inflammatory cytokines at 3 weeks. In addition, we measured sFRP-2 at 1, 7 and 21 
days post RMI.
Results: Compared to sham, RMI-placebo induced infarction (25% LV; 60% risk), LV remodeling and systolic and diastolic dysfunction. Compared 
to placebo, CN limited LV remodeling and dysfunction. Compared to non-infarct zones, RMI increased sFRP-2 and collagens as well as transforming 
growth factor (TGF)-β1, Smad-2, tumor necrosis factor (TNF)-α and interleukin (IL)-6, and decreased Ac-SDKP and IL-10. In contrast, CN blocked the 
increase in sFRP-2, normalized Ac-SDKP, TGF-β1, Smad-2 and TNF-α, restored IL-10, and decreased collagens in infarct/border zones. The effect of 
CN on sFRP-2 was evident on days 1, 7 and 21.
Conclusion: The overall results suggest that candesartan-induced suppression of sFRP-2 in the infarct/border zones might contribute to the 
limitation of post-RMI fibrosis and remodeling during healing post RMI.
